[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100585967":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":21,"locations":27,"responsibleParty":112,"collaborators":10,"id":114,"slug":10,"hasResults":115,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":115,"sex":121,"minAge":122,"maxAge":10,"enrollmentInfo":123,"targetDuration":10,"studyType":126,"phases":10,"briefSummary":127,"conditions":128,"keywords":130,"overallStatus":30,"whyStopped":10,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":143},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Ravulizumab",null,"Open-lable arm with gMG patients who received ravulizumab treatment in the frames of NDP in Poland.",[13],"Drug: Ravulizumab",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Ravulizumab, concentrate for solution for infusion",[9],[20],"Ultomiris",[22],{"name":23,"role":24,"phone":25,"phoneExt":10,"email":26},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[28,39,46,53,60,67,74,82,87,94,98,105],{"facility":29,"status":30,"city":31,"state":10,"zip":10,"country":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":10},"Research Site","RECRUITING","Bydgoszcz","Poland",{"type":34,"coordinates":35},"Point",[36,37],18.00762,53.1235,{"lat":37,"lon":36},{"facility":29,"status":30,"city":40,"state":10,"zip":10,"country":32,"cosmosGeoPoint":41,"geoPoint":45,"contacts":10},"Gdansk",{"type":34,"coordinates":42},[43,44],18.64912,54.35227,{"lat":44,"lon":43},{"facility":29,"status":30,"city":47,"state":10,"zip":10,"country":32,"cosmosGeoPoint":48,"geoPoint":52,"contacts":10},"Katowice",{"type":34,"coordinates":49},[50,51],19.02173,50.2597,{"lat":51,"lon":50},{"facility":29,"status":30,"city":54,"state":10,"zip":10,"country":32,"cosmosGeoPoint":55,"geoPoint":59,"contacts":10},"Krakow",{"type":34,"coordinates":56},[57,58],19.93658,50.06143,{"lat":58,"lon":57},{"facility":29,"status":30,"city":61,"state":10,"zip":10,"country":32,"cosmosGeoPoint":62,"geoPoint":66,"contacts":10},"Lodz",{"type":34,"coordinates":63},[64,65],19.47395,51.77058,{"lat":65,"lon":64},{"facility":29,"status":30,"city":68,"state":10,"zip":10,"country":32,"cosmosGeoPoint":69,"geoPoint":73,"contacts":10},"Lublin",{"type":34,"coordinates":70},[71,72],22.57009,51.25058,{"lat":72,"lon":71},{"facility":29,"status":75,"city":76,"state":10,"zip":10,"country":32,"cosmosGeoPoint":77,"geoPoint":81,"contacts":10},"WITHDRAWN","Poznan",{"type":34,"coordinates":78},[79,80],16.92993,52.40692,{"lat":80,"lon":79},{"facility":29,"status":83,"city":76,"state":10,"zip":10,"country":32,"cosmosGeoPoint":84,"geoPoint":86,"contacts":10},"NOT_YET_RECRUITING",{"type":34,"coordinates":85},[79,80],{"lat":80,"lon":79},{"facility":29,"status":30,"city":88,"state":10,"zip":10,"country":32,"cosmosGeoPoint":89,"geoPoint":93,"contacts":10},"Szczecin",{"type":34,"coordinates":90},[91,92],14.55302,53.42894,{"lat":92,"lon":91},{"facility":29,"status":83,"city":88,"state":10,"zip":10,"country":32,"cosmosGeoPoint":95,"geoPoint":97,"contacts":10},{"type":34,"coordinates":96},[91,92],{"lat":92,"lon":91},{"facility":29,"status":30,"city":99,"state":10,"zip":10,"country":32,"cosmosGeoPoint":100,"geoPoint":104,"contacts":10},"Warsaw",{"type":34,"coordinates":101},[102,103],21.01178,52.22977,{"lat":103,"lon":102},{"facility":29,"status":30,"city":106,"state":10,"zip":10,"country":32,"cosmosGeoPoint":107,"geoPoint":111,"contacts":10},"Wroclaw",{"type":34,"coordinates":108},[109,110],17.03006,51.10286,{"lat":110,"lon":109},{"type":113,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100585967",false,"NCT06909253","Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis","Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis (gMG) Naive to Complement Inhibitors. Prospective, Multicenter, Non-interventional Study (MG-ARCADIA).","MG-ARCADIA","Inclusion Criteria:\n\n* Adult (aged ≥18 years) patients with gMG, naive to complement inhibitors, receiving ravulizumab treatment in the frames of NDP in Poland.\n* Patients willing to participate in the study and signed Informed Consent Form (ICF).\n* Vaccination against N. meningitidis\n\nExclusion Criteria:\n\n* Those who plan to participate in gMG clinical trial on\u002Fafter the date of first ravulizumab infusion through NDP.\n* Cognitive incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.","ALL","18 Years",{"count":124,"type":125},50,"ESTIMATED","OBSERVATIONAL","The Polish multicentre observational (non-interventional) study aiming to collect data on the management and clinical outcomes of patients with gMG that received ravulizumab.",[129],"Myasthenia Gravis, Generalized",[9,131,132,133],"Generalized Myasthenia Gravis","gMG","observational","2026-06-17",{"date":136,"type":137},"2026-06-18","ACTUAL",{"date":139,"type":137},"2025-05-15",{"date":141,"type":125},"2029-12-31",{"name":5,"class":6},12]